Last updated 3 months ago
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
500 patients around the world
Available in Argentina, United States, Spain
Primary:
To evaluate the long-term safety and tolerability of seladelpar
Secondary:
- To evaluate the long-term efficacy of seladelpar
- To evaluate the effect of seladelpar on patient-reported outcomes (pruritus)
CymaBay Therapeutics, Inc.
10Research sites
500Patients around the world
Requirements for the patient
To 75 Years
All Gender
Medical requirements
Sites
CEDIMBA - DIM Clínica Privada - Buenos Aires
Recruiting
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Hospital Italiano de La Plata
Recruiting
Centro Clinico Mediterráneo
Recruiting
Hospital Universitario Virgen de la Victoria
Recruiting
Hospital Universitario Germans Trias i Pujol
Recruiting
Hospital Vall de Hebrón
Recruiting
Hospital Universitario 12 de Octubre
Recruiting
Hospital Universitario La Paz
Recruiting
SponsorCymaBay Therapeutics, Inc.
Study typeInterventional
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT03301506
